# A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.

Source: https://onco.cc/trials/nct06654947/  
OnCo record `nct06654947` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of toripalimab, gemcitabine, oxaliplatin and surufatinib in gallbladder cancer and other biliary tract cancers, run by Fujian Cancer Hospital, not yet recruiting.

## Summary

A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer. is a phase 2 interventional study registered as NCT06654947 by Fujian Cancer Hospital, with a registry enrolment figure of 23 participants, started 2025-01 and due to reach its primary completion in 2026-12. Interventions recorded: Surufatinib+Toripalimab+GEMOX. Conditions listed: Biliary Tract Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06654947
- Phase: 2
- Setting: A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.
- Sponsor: Fujian Cancer Hospital
- Enrolled: 23

## Sources

- ClinicalTrials.gov NCT06654947: https://clinicaltrials.gov/study/NCT06654947

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Surufatinib](https://onco.cc/drugs/surufatinib/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct06654947.json